Literature DB >> 12923179

Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.

George K Tofaris1, Azam Razzaq, Bernardino Ghetti, Kathryn S Lilley, Maria Grazia Spillantini.   

Abstract

Lewy bodies are intracellular fibrillar inclusions composed of alpha-synuclein. They constitute the pathological hallmark of Parkinson's disease, dementia with Lewy bodies, and other neurodegenerative diseases. Although the majority of Lewy bodies are stained for ubiquitin by immunohistochemistry, the substrate for this modification is poorly understood. Insoluble, urea-soluble alpha-synuclein was separated from soluble fractions and subjected to two-dimensional gel electrophoresis to further characterize pathogenic alpha-synuclein species from disease brains. By using this approach, we found that in sporadic Lewy body diseases a highly modified, disease-associated 22-24-kDa alpha-synuclein species is ubiquitinated. Conjugation of one, two, and, to a lesser extent, three ubiquitins was detected. This 22-24-kDa alpha-synuclein species represents partly phosphorylated protein. Furthermore, no generalized impairment of the proteolytic activity of the proteasome was detected in brain regions with Lewy body pathology. Because unmodified alpha-synuclein is degraded by the proteasome in a ubiquitin-independent manner, these data suggest that accumulation of modified 22-24-kDa alpha-synuclein is a disease-specific event which may overwhelm the proteolytic system, leading to aberrant ubiquitination. Accordingly, carboxyl-terminal-truncated alpha-synuclein, presumably the result of aberrant proteolysis, is found only in association with alpha-synuclein aggregates.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923179     DOI: 10.1074/jbc.M308041200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  117 in total

1.  SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease.

Authors:  Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K Tofaris; Michel Goedert; Maria Grazia Spillantini
Journal:  Brain       Date:  2010-06-09       Impact factor: 13.501

Review 2.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

3.  Ubiquitin proteasome pathway-mediated degradation of proteins: effects due to site-specific substrate deamidation.

Authors:  Edward J Dudek; Kirsten J Lampi; Jason A Lampi; Fu Shang; Jonathan King; Yongting Wang; Allen Taylor
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-30       Impact factor: 4.799

4.  Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway.

Authors:  George K Tofaris; Hyoung Tae Kim; Raphael Hourez; Jin-Woo Jung; Kwang Pyo Kim; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-27       Impact factor: 11.205

5.  Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway.

Authors:  Jochen Klucken; Anne-Maria Poehler; Darius Ebrahimi-Fakhari; Jacqueline Schneider; Silke Nuber; Edward Rockenstein; Ursula Schlötzer-Schrehardt; Bradley T Hyman; Pamela J McLean; Eliezer Masliah; Juergen Winkler
Journal:  Autophagy       Date:  2012-05-01       Impact factor: 16.016

Review 6.  Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology.

Authors:  Trevor Tyson; Jennifer A Steiner; Patrik Brundin
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 7.  New insight into neurodegeneration: the role of proteomics.

Authors:  Ramavati Pal; Guido Alves; Jan Petter Larsen; Simon Geir Møller
Journal:  Mol Neurobiol       Date:  2013-12-10       Impact factor: 5.590

8.  Synthetic polyubiquitinated α-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology.

Authors:  Mahmood Haj-Yahya; Bruno Fauvet; Yifat Herman-Bachinsky; Mirva Hejjaoui; Sudhir N Bavikar; Subramanian Vedhanarayanan Karthikeyan; Aaron Ciechanover; Hilal A Lashuel; Ashraf Brik
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-16       Impact factor: 11.205

9.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

10.  Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells.

Authors:  Li-Wen Ko; Hwai-Hwa C Ko; Wen-Lang Lin; Jayanranyan G Kulathingal; Shu-Hui C Yen
Journal:  J Neuropathol Exp Neurol       Date:  2008-11       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.